669 related articles for article (PubMed ID: 36389701)
1. Chimeric antigen receptor T cells applied to solid tumors.
Zhou Z; Tao C; Li J; Tang JC; Chan AS; Zhou Y
Front Immunol; 2022; 13():984864. PubMed ID: 36389701
[TBL] [Abstract][Full Text] [Related]
2. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
4. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
Yu T; Yu SK; Xiang Y; Lu KH; Sun M
Front Immunol; 2022; 13():936496. PubMed ID: 35903099
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
6. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
[TBL] [Abstract][Full Text] [Related]
8. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
9. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors.
Sun Z; Li R; Shen Y; Tan S; Ding N; Xu R; Wang X; Wei J; Liu B; Meng F
J Hematol Oncol; 2022 Mar; 15(1):29. PubMed ID: 35303900
[TBL] [Abstract][Full Text] [Related]
10. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
11. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
Dagar G; Gupta A; Masoodi T; Nisar S; Merhi M; Hashem S; Chauhan R; Dagar M; Mirza S; Bagga P; Kumar R; Akil ASA; Macha MA; Haris M; Uddin S; Singh M; Bhat AA
J Transl Med; 2023 Jul; 21(1):449. PubMed ID: 37420216
[TBL] [Abstract][Full Text] [Related]
12. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
13. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
14. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.
Daei Sorkhabi A; Mohamed Khosroshahi L; Sarkesh A; Mardi A; Aghebati-Maleki A; Aghebati-Maleki L; Baradaran B
Front Immunol; 2023; 14():1113882. PubMed ID: 37020537
[TBL] [Abstract][Full Text] [Related]
15. Coengineering specificity, safety, and function into T cells for cancer immunotherapy.
Giordano Attianese GMP; Ash S; Irving M
Immunol Rev; 2023 Nov; 320(1):166-198. PubMed ID: 37548063
[TBL] [Abstract][Full Text] [Related]
16. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
Zhou S; Sun H; Choi SI; Yin J
Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
[TBL] [Abstract][Full Text] [Related]
17. Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions.
Nguyen DT; Liu R; Ogando-Rivas E; Pepe A; Pedro D; Qdaisat S; Nguyen NTY; Lavrador JM; Golde GR; Smolchek RA; Ligon J; Jin L; Tao H; Webber A; Phillpot S; Mitchell DA; Sayour EJ; Huang J; Castillo P; Gregory Sawyer W
Acta Biomater; 2023 Dec; 172():466-479. PubMed ID: 37788737
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
Brookens SK; Posey AD
Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
Drougkas K; Karampinos K; Karavolias I; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Trontzas I; Kotteas E
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2709-2734. PubMed ID: 36564524
[TBL] [Abstract][Full Text] [Related]
20. Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
Li Y; Rezvani K; Rafei H
Immunol Rev; 2023 Nov; 320(1):217-235. PubMed ID: 37548050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
